BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target

NRX Pharmaceuticals, Inc. -1.66%

NRX Pharmaceuticals, Inc.

NRXP

1.78

-1.66%

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ: NRXP) with a Buy and maintains $25 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via